Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Anxiety Disord ; 52: 8-14, 2017 Dec.
Article de Anglais | MEDLINE | ID: mdl-28950218

RÉSUMÉ

Health anxiety (HA) refers to excessive worries and anxiety about harbouring serious illness based on misinterpretation of bodily sensations or changes as signs of serious illness. Severe HA is associated with disability and high health care costs. However, the impact of parental HA on excessive concern with their children's health (health anxiety by proxy) is scantly investigated. The aim of this study is to investigate HA by proxy in mothers with severe HA. Fifty mothers with severe HA and two control groups were included, i.e. mothers with rheumatoid arthritis (N=49) and healthy mothers (N=51). All participants completed self-report questionnaires on their own HA and illness perceptions and on illness worries and illness behaviour related to their children. The results showed that mothers with severe HA reported significantly more negative illness perceptions and more HA on behalf of their child (i.e. by proxy) compared to both control groups. HA by proxy may be an overlooked treatment target in mothers with severe HA, and improving our understanding of this condition can have important preventive and clinical implications.


Sujet(s)
Troubles anxieux/psychologie , Hypochondrie/psychologie , Mères/psychologie , Adolescent , Adulte , Troubles anxieux/thérapie , Études cas-témoins , Enfant , Femelle , Humains , Comportement de maladie , Mâle , Relations mère-enfant , Perception , Rôle de malade , Enquêtes et questionnaires
2.
J Rheumatol ; 44(1): 59-69, 2017 01.
Article de Anglais | MEDLINE | ID: mdl-27909080

RÉSUMÉ

OBJECTIVE: To compare baseline disease activity and treatment effectiveness in biologic-naive patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who initiate tumor necrosis factor inhibitor (TNFi) treatment and to study the role of potential confounders (e.g., HLA-B27 status). METHODS: Observational cohort study based on prospectively registered data in the nationwide DANBIO registry. We used Kaplan-Meier plots, Cox, and logistic regression analyses to study the effect of diagnosis (nr-axSpA vs AS) and potential confounders (sex/age/start yr/HLA-B27/disease duration/TNFi-type/smoking/baseline disease activity) on TNFi adherence and response [e.g., Bath Ankylosing Spondylitis Activity Index (BASDAI) 50%/20 mm]. RESULTS: The study included 1250 TNFi-naive patients with axSpA (29% nr-axSpA, 50% AS, 21% lacked radiographs of sacroiliac joints). Patients with nr-axSpA were more frequently women (50%/27%) and HLA-B27-negative (85/338 = 25%), compared to AS (81/476 = 17%; p < 0.01). At TNFi start patients with nr-axSpA had higher visual analog scale scores [median (quartiles)] for pain: 72 mm (55-84)/65 mm (48-77); global: 76 mm (62-88)/68 mm (50-80); fatigue: 74 mm (55-85)/67 mm (50-80); and BASDAI: 64 (54-77)/59 (46-71); all p < 0.01. However, patients with nr-axSpA had lower C-reactive protein: 7 mg/l (3-17)/11 mg/l (5-22); and BAS Metrology Index: 20 (10-40)/40 (20-50); all p < 0.01. Median (95% CI) treatment adherence was poorer in nr-axSpA than in AS: 1.59 years (1.15-2.02) versus 3.67 years (2.86-4.49), p < 0.0001; but only in univariate and not confounder-adjusted analyses (p > 0.05). Response rates were similar in AS and nr-axSpA (p > 0.05). HLA-B27 negativity was associated with poorer treatment adherence [HLA-B27 negative/positive, nr-axSpA: HR 1.74 (1.29-2.36), AS: HR 2.04 (1.53-2.71), both p < 0.0001]; and lower response rates (nr-axSpA: 18/61 = 30% vs 93/168 = 55%; AS: 17/59 = 29% vs 157/291 = 54%, both p < 0.05). CONCLUSION: In this nationwide cohort, patients with nr-axSpA had higher subjective disease activity at start of first TNFi treatment, but similar outcomes to patients with AS after confounder adjustment. HLA-B27 positivity was associated with better outcomes irrespective of axSpA subdiagnosis.


Sujet(s)
Antirhumatismaux/usage thérapeutique , Produits biologiques/usage thérapeutique , Antigène HLA-B27/sang , Spondylarthrite/traitement médicamenteux , Pelvispondylite rhumatismale/traitement médicamenteux , Adulte , Études de cohortes , Femelle , Humains , Mâle , Adhésion au traitement médicamenteux , Adulte d'âge moyen , Enregistrements , Articulation sacro-iliaque/imagerie diagnostique , Indice de gravité de la maladie , Spondylarthrite/imagerie diagnostique , Spondylarthrite/génétique , Pelvispondylite rhumatismale/sang , Pelvispondylite rhumatismale/imagerie diagnostique , Résultat thérapeutique , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE